Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension Double-blind, randomized, multicenter, multinational, placebo-controlled phase IIa study
This study is looking into a new medicine called riociguat for people who have early signs of a lung condition affecting the blood vessels. This condition can lead to high blood pressure in the lungs, known as pulmonary arterial hypertension. The main goal is to find out if riociguat can improve how easily blood flows through the lungs and if it's safe to use. Some people in the study will get the actual medicine, while others will get a dummy pill (placebo). This helps researchers fairly compare the effects. They will also check if it helps with things like how far people can walk and their general quality of life. The study involves hospitals in different countries and includes adults aged 18 and over.
At a glance
What is this study about?
This research study is about a medicine called riociguat, and it's for people who are showing very early signs of a condition where the blood vessels in their lungs start to become narrow. If these vessels get too narrow, it can make it harder for the heart to pump blood through the lungs, leading to high blood pressure in the lungs, also known as pulmonary arterial hypertension (PAH).
The main aim of this study is to see if riociguat can help to relax and open up these lung blood vessels, making it easier for blood to flow through. The researchers want to understand if this medicine is both effective and safe for people who are just starting to develop these lung vessel problems. By treating the condition early, there's hope that it might prevent it from getting worse.
To make sure the results are fair, some people taking part will receive the actual riociguat medicine, while others will get a dummy pill (called a placebo). Neither the patients nor their doctors will know who is getting which, until the study is over. This is a common and important way to test new medicines. The study will also measure other health aspects, like how well people can breathe, how far they can walk in a set time, and how their general health and well-being are affected.
Key takeaways
- This study is testing a new medicine for early lung blood vessel problems.
- It aims to see if the medicine improves blood flow and is safe.
- Some participants will receive the active medicine, others a dummy pill.
- The study lasts about 6 months, with regular checks.
- It's for adults aged 18 and older, both men and women.
- You can stop participating at any time.
Who may be eligible?
To be part of this study, you must be at least 18 years old. The study is open to both men and women.
Doctors will carefully check your health to make sure you have early signs of the lung blood vessel condition the study is focusing on. They will also look at your overall health to ensure it's safe for you to take part in the study and to take the medicine being tested.
There might be other health conditions or medicines that would prevent you from joining, so a doctor involved in the study will need to review your full medical history.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you male or female?
- Have you been told you have early signs of a lung condition affecting your blood vessels?
- Are you generally able to attend regular hospital appointments over 6 months?
- Are you willing to take a study medicine or dummy pill as instructed?
What does participation involve?
If you decide to take part in this study, you will be in it for about 24 weeks, which is roughly six months. During this time, you'll have several visits to the clinic or hospital. At these visits, doctors will perform various tests and assessments, such as checking your lung function, blood pressure, and how far you can walk in six minutes.
You will be given either the study medicine (riociguat) or a dummy pill (placebo) to take regularly, as instructed by the study team. You won't know which one you are receiving. The study team will monitor you closely for any changes in your health or side effects. After the 24 weeks of treatment, there will likely be follow-up appointments to check on your health and gather final study information.
Potential risks and benefits
Locations (4)
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedAustria
- —UnverifiedItaly
Common questions
What is 'pulmonary arterial hypertension'?
It's a serious condition where the blood pressure in the arteries that go from your heart to your lungs becomes too high, making your heart work much harder.
What does 'double-blind' mean?
It means neither you nor your doctor will know if you are getting the active medicine or a dummy pill (placebo) until the study ends. This helps make the results fairer.
What is a 'placebo'?
A placebo is a dummy pill that looks just like the study medicine but contains no active ingredients. It's used to see the true effect of the actual medicine.
Will I have to pay to join the study?
No, you will not have to pay to participate in the study. All study-related care and medication are provided free of charge.
How long will the study last for me?
Your active participation in the study, including taking the medicine or placebo, will last for about 24 weeks (roughly 6 months).
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.